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We have used site-directed mutagenesis to change amino acid residues in the heavy chain of the 
pathogenic R4A anti-double-stranded DNA (dsDNA) antibody and have looked for resultant 
alterations in DNA binding and in pathogenicity. The data demonstrate that single amino acid 
substitutions in both complementarity determining and framework regions alter antigen binding. 
Changes in only a few amino acids entirely ablate DNA specificity or cause a 10-fold increase 
in relative binding. In vivo studies in mice of the pathogenicity of the mutated antibodies show 
that a single amino acid substitution leading to a loss of dsDNA binding leads  also to a loss 
of glomerular sequestration. Amino acid substitutions that increase relative affinity for dsDNA 
cause a change in localization of immunoglobulin deposition from glomeruli to renal tubules. 
These studies demonstrate that small numbers of amino acid substitutions can dramatically alter 
antigen binding and pathogenicity, and that the pathogenicity of anti-DNA antibodies does 
not strictly correlate with affinity for DNA. 
nti-double-stranded  DNA  (dsDNA) 1  antibodies  are 
present in the serum of patients with SLE. The fluctu- 
ation in titer of these antibodies in association with disease 
activity (1) and their presence in the kidneys of lupus patients 
(2) have led investigators to believe they are involved in the 
pathogenesis of the disease,  specifically in the development 
of lupus glomerulonephritis. Over the past several years,  a 
number of studies of the molecular genetics and protein struc- 
ture of anti-dsDNA antibodies have been undertaken as a way 
of trying to understand: (a) whether the anti-DNA response 
in SLE is elicited by antigen, and, if so, whether that antigen 
is DNA, another self antigen, or a foreign antigen; (b) what 
particular  features  of these  antibodies  account  for DNA 
binding; and (c) what are the determinants of pathogenicity 
of anti-DNA antibodies (3-6). 
Mutational analyses of anti-DNA antibodies have been per- 
formed to try to elucidate whether DNA binding specificity 
represents part of an antigen-selected response. Clustering 
of replacement (R) base changes that lead to an amino acid 
change in CDRs is one measure commonly used to suggest 
antigen selection (7).  This is clearly based on the primacy 
of CDtLs  in  determining antigen  specificity and  affinity. 
Second, the ratio of tL mutations to silent (S) base changes 
that do not lead to a change in amino acid, has been calcu- 
lated. R/S ratios greater than random are thought to be evi- 
dence for antigen selection. B cell genealogies have been es- 
peciaUy useful in these analyses as they identify those mutated 
1 Abbreviations used in this paper: dsDNA, double-stranded  DNA; FR, 
framework  region; R/S ratio, ratio of replacement  mutations  to silent  base 
changes; ss, singh-stranded  DNA. 
progeny of a single B cell that are amplified in vivo. Whereas 
several studies have been interpreted as showing the anti-DNA 
response is antigen driven (3, 4, 6, 8, 9), other studies have 
shown that many anti-DNA antibodies do not meet criteria 
for antigen selection and have raised the question whether 
other forces are operative in the anti-DNA response (10). 
Sequence analysis of anti-dsDNA antibodies has led to the 
speculation that certain amino acids are present in the CDRs 
of anti-DNA antibodies at a higher frequency than in anti- 
bodies with other antigenic specificities.  These amino acids 
include arginine, lysine, tyrosine, glutamine, and asparagine. 
In particular, arginine residues in the H chain have been im- 
plicated in dsDNA binding (4) as arginine has the potential 
to interact with the phosphodiester backbone of dsDNA or 
with cytosine-guanine base pairs (11). Whereas the presence 
of arginine residues in the CDR3 is striking, it is important 
to recognize that approximately one third of anti-dsDNA 
antibodies have no arginine in CDR3. Furthermore, the re- 
cent crystallographic analysis  of an antitrithymidilate anti- 
body (12) suggests that many amino acid residues participate 
in binding to DNA. 
Finally,  the determinants of pathogenicity of anti-DNA 
antibodies have been examined. It is clear that cationic anti- 
DNA antibodies are, in general, more likely to deposit in 
glomeruli than neutral or anionic antibodies (13),  yet not 
all cationic anti-DNA antibodies are pathogenic. Some studies 
have suggested that pathogenic anti-DNA antibodies cross- 
react with tubular antigens since lupus nephritis may include 
tubular as well as glomerular disease  (14,  15). It has been 
suggested that tubular deposition of Ig occurs when immune 
complexes are large, whereas smaller complexes cause glo- 
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sequestration and pathogenicity are not yet defined at a mo- 
lecular level. 
We present in this paper an analysis of in vitro-generated 
mutants of a murine anti-dsDNA  antibody. We selected to 
delete or insert arginines to test the importance of this amino 
acid in DNA binding.  Mutations were made in both CDRs 
and framework regions (FRs). We wished also to ask whether 
a change in  charge of the V  region  was  sufficient to alter 
DNA binding or whether only changes in charge within the 
antigen binding site would alter antigen binding. In two mu- 
tants we removed a negatively charged residue to test whether 
these also contribute to dsDNA  binding  as has been sug- 
gested by Ohnishi et al. (16). The relative binding to DNA 
of the mutant antibodies was measured. In addition, the renal 
sequestration of some of these antibodies was determined in 
SCID  mice. 
Materials  and  Methods 
Isolation of a L  Chain-secreting R4A  Cell Line.  The R4A cell 
line was derived from a BALB/c mouse immunized with phosphoryl- 
choline (PC)  conjugated  to human  gamma  globulin  (17). The 
secreted antibody binds dsDNA on a filter assay (Millipore Corp., 
Bedford, MA) and on an ELISA, and is encoded by the unmutated 
germline $107 Vll H chain gene and an unmutated germline V,1 
L chain gene. 
A cell line secreting only the R4A L chain was isolated by soft 
agarose cloning and overlayed with rabbit anti-mouse IgG antiserum 
kindly provided by Dr. Matthew Scharff (Albert Einstein College 
of Medicine) (18), Absence of Ig H  chain expression  in selected 
clones was confirmed by RNA dot blot using a probe that hybrid- 
izes to the H  chain V region (19). Continued expression of the 
R4A L chain was ascertained by an ELISA for K L chain in culture 
supernatant and RNA dot blot of cells using a V,1 probe that hy- 
bridizes  to the R4A L chain. 
Oligonucleotide-directed Mutagenesis.  A  plasmid containing an 
EcoRI-EcoKI 3.5-kb rearranged V region gene of the R4A H chain 
(pBluescript SK; Stratagene Cloning Systems,  La Jolla, CA) was 
used as the template for the mutagenic PCR reactions (20).  All 
PCR reactions were performed in a thermal cycler (Perkin Elmer 
Cetus, Norwalk,  CT) using the following program:  1.5 rain at 
96~  and 3.5 min at 72~  for 30 cycles. The primary reactions, 
25-30 ng of plasmid DNA and 250 ng of each primer were used. 
In the secondary PCR reaction, 1% of the two primary reactions 
and 250 ng of each of the 5' and 3' flanking primers were added. 
The PCR reaction mix consisted of 1.5 mM MgC12, 0.25 mM 
dNTPs, lx  Taq buffer (10x  =  100 mM Tris-HC1,  pH 8.3, 500 
mM KC1, and 0.1% gelatin), and 1 txl Taq polymerase (Perkin Elmer 
Cetus). For the primary PCR reactions, each mutagenic oligomer 
was used with an appropriate antisense 3' or sense 5' V region gene 
flanking oligomer containing a HindlII or EcoRI site, respectively, 
plus a GGG clamp.  The 5' flanking oligomer is complementary 
to sequences 500 bp 5' of the Vll genomic DNA. The 3' oligomer 
is complementary to sequences 30 bp 3' of  J~4. Each pair of PCR 
products served as templates for the secondary reaction to generate 
full-length V region genes containing the desired mutations. One 
PCR reaction generated the wild-type R4A H chain sequence as 
a control for all subsequent analyses. 
Each PCR product was isolated  from a 0.8% agarose gel and 
purified through an Elutip-D minicolumn (Schleicher & Schuell, 
Inc., Keene, NH). After digestion with 50-100 U of Hindlll and 
EcoRI, the PCR product was used in a standard ligation reaction. 
Plasmid Construction.  The "y2b C  region and gpt-containing 
plasmid,  p368, was generously provided by Dr. Jacqueline Sharon 
(Boston University, Boston, MA) (21). It contains the C'y2b gene, 
Ig H chain enhancer, and the selectable marker gpt, and has unique 
5' EcoRI and 3' HindlII sites into which each EcoRI/HindlII PCR- 
generated V, gene segment (0.9 kb) was  inserted. 
DNA Transfection.  L chain-secreting R4A cells were transfected 
by electroporation with plasmids  encoding the wild-type or mu- 
tant R4A H chain V region genes (22). For each transfection reac- 
tion, 3  x  106 cell in 0.3 ml and 1-40 #g circular plasmid DNA, 
1-40 #g, were used. After electroporation, cells were resuspended 
in 10 ml of selective (HX) medium, 1% L-glutamine (Mediatech, 
Hemdon, VA), 1% penicillin-streptomycin  (Mediatech), 1% nones- 
sential  amino acids, 0.003%  fungizone, 0.002%  gentamicin (all 
from GIBCO BRL, Gaithersburg, MD), 10 mM Hepes, pH 7.4, 
0.15 mg/ml hypoxanthine, and 0.25 mg per ml xanthine (all from 
Sigma Chemical Co., St. Louis,  MO), brought up to volume in 
IMDM (GIBCO BILL) supplemented with 20%  FCS (Hyclone 
Labs., Logan, UT) and 10% supernatant from Con A-stimulated 
mouse spleen cells, and plated into 96-well  tissue  culture plates 
(Becton Dickinson, Lincoln Park, NJ). After incubation at 37~ 
for 24-48 h,  6 #g/ml mycophenolic acid (Sigma Chemical Co.) 
was added to the culture medium. Surviving clones were screened 
for secretion of the H  chain. 
Purification of Antibodies.  mAbs were purified from culture su- 
pernatants  by  elution  (0.1  M  glycine,  pH3)  from  a  protein 
G-Sepharose column on a fast protein liquid chromatography ap- 
paratus (Pharmacia,  Piscataway,  NJ). 
Quantitation  of Antibodies.  96-well  microtiter  ELISA  plates 
(Becton Dickinson) were coated with  a  1:500 dilution of goat 
anti-mov.se IgG2b (Fisher Scientific Co., Pittsburgh, PA) for ei- 
ther 1 h at 37~  or overnight at 4~  Wells were blocked with 
2% BSA in PBS, washed with PBS, 0.05% Tween 20, and incubated 
for 1 h at 37~  with serial dilutions of culture supernatants, serum 
from tumor-bearing mice, or twofold dilutions of a commercially 
purified IgG2b standard. After washing, wells were incubated with 
a 1:1,000 dilution of alkaline phosphatase-linked goat anti-mouse 
IgG2b (Fisher Scientific) for 1 h and finally developed with alkaline 
phosphatase  substrate  (p-nitrophenyl  tablets  phosphate,  Sigma 
Chemical Co.). The reaction was monitored at 405  nm. 
k-g/2b ELISA.  The k-3'2b  ELISA  was  similar  to the Cy2b 
ELISA protocol described above but with the following modifica- 
tions: (a) goat anti-mouse tc chain antibody (Fisher Scientific) was 
diluted 1:500 in PBS and adsorbed to a 96-well microtiter plate 
for 2 h at 37~  and (b) purified antibodies were normalized to 
5 #g/ml in blocking solution and added after block at 37~  for 
I h. Alkaline phosphatase-conjugated goat anti-mouse IgG2b was 
added for 1 h and the assay was developed with phosphatase sub- 
strate. 
Anti-idiotypic ELISA.  A monoclonal IgG1 anti-idiotypic reagent 
9B4 that reacts with S107 VII-encoded H chains  was generated 
by Dan Lustgarten (Albert Einstein College of Medicine).  The 
ELISA was performed as follows. An ELISA plate was coated with 
1 #g antibody at 37~  for 1-2 h.  It was blocked, washed,  and 
incubated with a 1:100 dilution in PBS of 9B4 cell supernatant, 
followed by an alkaline phosphatase-linked, goat anti-mouse IgG1 
(Fisher  Scientific)  and developed  in a standard manner. 
ELISAs for Antigenic  Specificity.  The dsDNA ELISA used is 
a modification of the assay of Miller et al. (23).  Round-bottom 
polyvinyl plates (Becton Dickinson) were coated with poly-L-lysine 
926  Mutational Analysis of an Autoantibody (1/~g/well) for 2 h at 37~  Calf thymus DNA was dissolved  in 
lx SSC at 4~  and filtered through a 0.45-M nitrocellulose  Millex 
syringe filter (Millipore Corp.) to obtain dsDNA. 100/~1 of dsDNA 
at an OD 260 of 0.75 was added to each well. The plates were 
blocked with 2% BSA/PBS for 1 h at 37~  and then incubated 
with 100/~I of purified antibody at 5/~g/ml for I h at 37~  Anti- 
3r  antibody diluted 1:1,000 was added for I h at room tempera- 
ture followed by substrate. To prepare ssDNA, calf thymus DNA 
was dissolved  in lx  SSC, boiled for 15 min, and put on ice. The 
ssDNA was also plated on poly-r-lysine-coated plates. 
To measure KNA binding, microtiter plates were coated with 
1/~g tKNA for 90 min at 37~  Purified protein was tested at 
5/~g/ml. 
PC ELISA.  The ELISA for PC binding was performed as de- 
scribed above  with the following  modifications:  (a) the ELISA  plates 
were coated with PC-KLH at 50/ig/ml for 2 h at 37~  and (b) 
mAbs were normalized to 10/lg/ml. 
dsDNA Millipore Filter Inhibition Assay.  Unlabeled calf thymus 
dsDNA (Calbiochem-Novabiochem  Corp., La Jolla, CA) in PBS 
was plated at various dilutions into each well of a Milliliter-HA 
96-well filtration plate (Millipore Corp.). Purified antibody at a 
concentration of 5 #g/ml was preincubated with 10/~1 of 32p_ 
labeled dsDNA at 1,500 cpm//~l for 1 h and then added to each 
well. The plate was incubated for an additional hour at 37~  The 
samples were filtered through the plate and washed four to five 
times with lx SSC on a 96-well vacuum filtration apparatus (Mil- 
lipore Corp.). The wells were punched out and counted. 
In Vivo Studies of  Renal Pathology.  2 wk after pristane priming, 
6-8-wk-old SCID mice were injected, intraperitoneally, with 107 
cells. Five mice in each group were examined every week for pro- 
teinuria and serum levels of IgG2b. Proteinuria was examined by 
multistix (Miles Inc., Elkhart, IN).  These mice were killed 1-2 
wk after ascites and/or tumors developed. All mice used in this 
study had equivalent titers of IgG2b in their serum by ELISA (see 
above). 
One kidney from each animal was fixed in 10% formalin and 
embedded in paraffin. Depositions of IgG antibodies in glomeruli 
were studied in 4-/im kidney sections which were deparaffinized, 
rehydrated, blocked with 2% BSA, stained with biotinylated goat 
anti-mouse IgG (Vector Laboratories, Inc., Burlingame, CA), then 
washed and developed with BCIP (5-Bromo-4-chloro-3-indolyl- 
phosphate p-toluidine salt) and NBT (Nitroblue Tetrazolium  Chlo- 
ride) substrates (GIBCO BRL). The stained sections were viewed 
with a Zeiss fluorescence microscope. 
Results 
Generation and Characterization of the R 4A Mutants.  R4A 
is a murine anti-dsDNA antibody. The H  chain is encoded 
by $107 Vll  and J.4 gene segments,  and an unknown D 
gene segment; the L chain by a member of the VK1 gene 
family and JR1. The R4A  H  chain was  subjected to  site- 
directed mutagenesis to study the effects of amino acid replace- 
ments on antibody affinity for dsDNA and/or fine specificity 
and pathogenicity. Mutant R4A H chain genes in a construct 
with the gpt gene were generated and transfected into an R4A 
H chain loss variant. The H chain V region sequence of the 
antibodies described in this report are given in Table 1. Three 
mutants 52, 85,  and 95 were generated with single amino 
acid substitutions that alter the charge of the V region. 52 
has a loss of a positively charged arginine at residue 52 in 
CDR2,  95 has a negatively charged residue removed from 
CDR3, and 85 has a loss of a negatively charged residue in 
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FR3. The other mutants have multiple amino acid substitu- 
tions. Whereas most were designed to test the importance 
of arginine in dsDNA binding, some arose serendipitously. 
In  8382b  and 9636,  arginine was removed from FR3  or 
CDR3, respectively. In the three remaining mutants, 52b3, 
52b6, and 6634, additional substitutions were made in charged 
amino acid residues. Arginine was removed from FR3 of 52b3. 
This same arginine was removed in 6634,  but an arginine 
was reinserted into FR3 closer to CDR3.  In 52b6  a lysine, 
also  a  positively charged amino  acid,  was  removed from 
CDR2. 
To confirm that the antibodies secreted by the transfec- 
tants show proper association of H  and L chains,  the wild- 
type and mutant antibodies were assayed in two ways. The 
first method utilizes an ELISA assaying for the coexpression 
of both H  and L chain determinants on a single antibody 
molecule (Fig.  1). All antibodies displayed associated H  and 
L chains, demonstrating that none of the mutations interfere 
with the assembly of H and L chains. The second assay tests 
for $107 Vll idiotype expression.  The reactivity of the mu- 
tated antibodies was compared to that of the wild-type R4A 
molecule. All the mutants tested are recognized by the 9B4 
anti-idiotype although three have slightly diminished reac- 
tivity (Fig. 2).  We conclude that the H  and L chains of all 
the transfected antibodies associate and that the H chain re- 
tains idiotypic expression. 
We utilized a dsDNA ELISA to measure the relative binding 
of the wild-type and mutant antibodies to dsDNA (Fig. 3). 
The wild-type R4A shows midrange binding; there are mu- 
tants with no detectable dsDNA binding and mutants with 
markedly enhanced dsDNA binding. An inhibition assay was 
performed on antibody 52b3 with the highest relative binding 
for dsDNA in order to quantitate its change in apparent affinity 
(data not shown). From these data and using a formula de- 
rived by Nieto et al. (24) for measuring the apparent affinity 
of antibodies to antigens containing multiple repeated anti- 
genic epitopes,  one can calculate  an apparent affinity (aKa) 
for 52b3  of ,x,1.77  x  101~  compared to 1-2  x  109 for the 
parental antibody. The mutants, therefore, range from no ap- 
preciable binding to dsDNA to a 10-fold increase in dsDNA 
binding. 
To see if any of the mutations resulted in new antigenic 
specificities, the antibodies were tested for binding on a panel 
of structurally related antigens: ssDNA, RNA, and PC. The 
results of the ssDNA ELISA demonstrate that the wild-type 
R4A antibody does not bind single-stranded DNA (ssDNA) 
(Fig.  4 a).  52b3,  which displays the most marked increase 
in affinity  for dsDNA, also shows reactivity to ssDNA. Mu- 
tant  6634  likewise  shows  increased  ssDNA  and dsDNA 
binding on ELISA. Alterations in dsDNA and ssDNA binding 
are not always coordinate; mutant 52 demonstrates increased 
dsDNA reactivity but displays no acquisition of ssDNA re- 
activity. 
The tRNA ELISA shows that neither the wild-type R4A 
antibody nor any mutant has specificity for this antigen (Fig. 
4 b). The wild-type R4A antibody displays little reactivity 
to PC. Three of the mutants, however, seem to have gained 
reactivity to PC (Fig. 4 c). Mutant 52b3, which demonstrates Table  1.  R 4A  Wild-type  and Mutant H  Chain  Sequences 
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Antibodies  are  ordered  from highest DNA binding (top) to no DNA binding (bottom). CDR.s  are denoted by bold letters  and are underlined. 
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1. 
IgG2b-kappa  ELISA 
Association  of 3"2b H chain with x L chains. Anti-K chain  Figure  1. 
antibody was adsorbed  to microtiter plates. Purified protein was added, 
followed by an enzyme-linked  anti-3,2b antibody. Absorbance at OD 405 
was determined.  The data in this assay are representative of several assays. 
e~ 
$107  Vll  Idiotype  Expression 
Q 
Figure  2.  Expression of an $107 Vll determinant.  Purified protein was 
adsorbed to microtiter plates. An IgG1 antibody specific for the $107 Vll 
gene product was added, followed by an enzyme-linked anti-y1 antibody. 
Absorbance at OD 405 was determined.  The data in this assay are repre- 
sentative of several assays. 
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dsDNA  Binding 
Figure  3.  Binding to dsDNA. Binding to dsDNA was determined using 
an ELISA that measures binding to dsDNA bound to poly-r-lysine coated 
wells.  Data in this assay are representative of several assays. 
increased binding activity to dsDNA and ssDNA, displays 
the highest PC binding. Mutants 6634 and 85, which both 
bind dsDNA slightly better than the wild-type antibody, also 
display PC binding. 
Three antibodies were assayed for pathogenicity, the pa- 
rental R4A, 95, which has no detectable dsDNA binding, 
and 52b3,  which displays the greatest increase in dsDNA 
binding. SCID mice were injected intraperitoneaUy with R4A 
cells or cells from the mutant lines, and mice displaying equiva- 
lent titers of IgG2b antibody in serum were used in this study 
(#g/ml R4A: 20, 39, 42, 61; 95: 8, 13, 18, 42, 75; and 52b3: 
3, 16, 16, 18, 50). All mice carrying an R4A or 52b3 tumor 
developed significant proteinuria. The mutant 95 did not cause 
proteinuria  in  any mice.  As  shown in  Fig.  5,  immuno- 
histochemical analysis demonstrated that R4A antibody is 
deposited in glomeruli in all mice. Antibody 95 is not se- 
questered in the kidney in any mice, consistent with its loss 
of DNA binding. Most surprisingly, all mice producing the 
52b3 antibody showed some glomerular deposition of IgG2b 
but a more striking deposition of IgG2b in renal tubules. 
Thus the change in affinity demonstrated by the antibody 
also led to a change in renal localization. 
Discussion 
We have generated in vitro a genealogy of antibodies de- 
rived from the R4A parental cell line. The R4A line binds 
dsDNA  and is  deposited in renal  glomeruli.  Changes in 
specificity, relative affinity, and pathogenicity were measured￿9 
The following amino acids were targeted for substitution￿9 
(a) Arginine residues were replaced with serine in CDR2, 
CDR3, and FR3 since arginine is the amino acid most closely 
associated with dsDNA binding; (b) lysine was targeted since 
it is also a basic amino acid and is present in the nucleotide 
binding sites of an anti-ssDNA antibody and other DNA 
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RNA  Binding 
PC  Binding 
I 
Binding to dsDNA-related antigens. Binding to ssDNA, RNA 
and PC was performed by ELISA as described in Materials  and Methods. 
All assays are representative of several assays. Figure  5.  Kidney  deposition  of R4A and its mutants.  Kidney  sections  from  6-8-wk-old  SCID mice  given  receiving  R4A or mutant  cells  were  stained 
with biotinylated  anti-IgG.  Immune  deposits  were  visualized  in glomeruli  for R4A and preferentially  in tubules  for the 52b3 mutant.  No IgG deposition 
was observed for the 95 mutant. 
binding proteins (12, 25); and last, (c) the acidic amino acids, 
glutamic acid and aspartic acid, were substituted in FR3 and 
CDR3, respectively.  If charge alone is important in the in- 
teraction with DNA, then the presence of aspartic  acid and 
glutamic acid should inhibit interactions with DNA. 
R4A GENEALOGIES 
~  ~dsDNA 0.707 
dsDNA 1.294  dsDNA  0.793  dsDNA  0.283 
R• 
dsDNA  0.707 
5V:M 
dsDNA 1,2S  dsDNA  0.480 
dsDNA 2.258  dsDNA 0.483  dsDNA 1.560 
Figure  6.  Genealogies  of R4A mutants. One genealogy  shows vari- 
ants with single  amino acid substitutions. The second genealogy  shows 
variants with two- to three-amino  acid  substitutions.  The amino  acid  sub- 
stitutions and the dsDNA binding are shown for each variant. 
Three mutants with single amino acid changes were iso- 
lated (Fig.  6).  Mutant 52 has one amino acid substitution, 
52 arginine to Ser in CDR2. It demonstrates higher binding 
than R4A to dsDNA, showing that an arginine may be lost 
within  a  CDR  without  a  resulting  decrease  in  dsDNA 
binding. The second mutant in this class, 85, has an 85 glu- 
tamic acid to glutamine replacement in FR3 and shows  a 
modest increase in dsDNA binding, demonstrating that FR 
substitutions can alter DNA binding. Mutant 95, with a 95 
aspartic acid to glycine replacement in CDR3 is notable for 
its loss of binding to dsDNA.  The fact that the loss of a 
negatively charged amino acid  leads  to decreased  dsDNA 
binding is surprising as positively charged amino acids have 
been implicated in DNA binding. Even more significant is 
the finding that this antibody, which is more cationic than 
the parental R4A, is no longer sequestered in glomeruli. Cat- 
ionic antibodies are thought to be preferentially sequestered 
in glomeruli because of their interaction with anionic base- 
ment membrane. This suggests that both antigenic specificity 
and charge are important in generating pathogenicity. 
The other mutants with multiple amino acid changes can 
be organized into an artificially generated B cell genealogy 
based on shared mutations (Fig. 6). Some structural conclu- 
sions can be drawn from the analysis of these more complex 
mutants. First, CDRs contain amino acids which are critical 
to the antigenic specificity of R4A. As expected, basic amino 
acids residues  52b and 96 can contribute to DNA binding. 
Residues 66, 82b,  and 83  in FR3 of the H  chain can have 
a significant influence on the specificity and affinity  of an anti- 
DNA antibody. A substitution in residue 66, like residue 85, 
is associated with both a change in affinity and the acquisi- 
tion of new fine specificities. 
It is interesting to note that two of the replacement muta- 
tions presented in this paper represent substitutions of invar- 
iant residues  (26).  52b lysine and 83 arginine, are mutated 
to alanine and serine, respectively. All of the proteins which 
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tein by the r-y2b ELISA and the $107 Vll idiotypic ELISA. 
Conformational information regarding these antibodies will 
depend on obtaining crystallographic data, but the demon- 
stration  that  they are  secreted in culture,  show normal  as- 
sociation of H and L chains,  and maintain an idiotypic marker 
argues against the notion that the presence of these residues 
is required either for transport and secretion or for maintaining 
gross conformation. Similar results were obtained by Sharon 
(27) when she mutated an invariant residue of the H  chain, 
36 tyrosine. It is not clear why the invariant residues are con- 
served but one tempting  speculation is that the role of the 
evolutionarily maintained invariant residues lies in the need 
to preserve idiotypic regulatory epitopes. 
The 52b3 antibody which is mutated at three residues in 
FR3  of  the  H  chain  has  a  dramatic  alteration  in  renal 
pathology. Whereas it continues to show some glomerular 
deposition, it is now deposited to a far greater extent in tubules, 
suggesting that the change affinity for dsDNA is also associated 
with  the acquisition  of a novel antigenic  cross reactivity. 
A major conclusion from the study of these mutant anti- 
bodies is that  one or a few amino  acid differences can alter 
antigen binding.  This  has  been shown previously with  an 
in vitro-generated mutant of a mouse myeloma cell line (28) 
and with B cell genealogies obtained by somatic cell fusion 
(29, 30). Whereas expressed antibody molecules often dis- 
play many amino acid differences from the germline template, 
only one or two of these may be significant in changing anti- 
genic specificity or affinity.  Antibodies with only one or a 
few mutations  would not be identified as antigen-selected 
antibodies in a mutational analysis where numbers of substi- 
tutions or R/S ratios are scored yet may display marked differ- 
ences in antigen binding.  This demonstrates the limitations 
of mutational analyses that do not also monitor affinity and 
specificity. Furthermore, the results of some of the mutations 
reported there suggest that we cannot yet accurately predict 
those residues that  are  critical  to DNA binding. 
A second conclusion is that FR determinants do not serve 
a purely scaffolding function;  they can influence antigenic 
fine specificity and affinity. Others have also shown that amino 
acid replacements in FR can affect antigen binding (31-33). 
Behar et al. (5) described a panel of anti-dsDNA antibodies 
derived from an autoimmune mouse in which some of the 
antibodies with high  affinity dsDNA binding  have a high 
R/S ratio in the FRs. Perhaps the replacement mutations in 
FR helped create dsDNA binding specificity either by direct 
interaction  with  antigen  or through  distal conformational 
effects. 
The most dramatic finding of this study is that a very few 
amino acid substitutions can completely abrogate pathoge- 
nicity or alter the in vivo target of a pathogenic autoanti- 
body. The observation that two closely related antibodies that 
differ in affinity for dsDNA binding R4A and 52b3 are dis- 
cordant with respect to localization of renal deposition raises 
the question of whether DNA binding is central or incidental 
to the pathogenicity of these antibodies.  It seems unlikely 
that DNA is differentially present in glomeruli where it is 
recognized by R4A and tubules where it bound by 52b3, 
or even that DNA-anti-DNA complexes are differentially  har- 
bored in these sites. More likely, anti-DNA antibodies cross- 
react with renal antigens, often with glomerular antigens but 
occasionally with tubular antigens. Others have demonstrated 
direct binding of anti-DNA antibodies to glomerular or cell 
surface antigens (14, 15), also suggesting that DNA binding 
may be an epiphenomenon  of lupus autoantibodies.  The as 
yet undefined cross-reactivities of anti-DNA antibodies may 
well represent their important  autoantigenic  specificities  in 
the pathogenesis of SLE. 
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